New directions in RVO treatment: Recent data have improved our understanding of BRVO and CRVO to better manage our patients

Retina Today

Volumn , Issue APRIL SUPPL., 2010, Pages 3-7

  Brown, David M ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 82255189638     PISSN: None     EISSN: 18250572     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Rogers S, McIntosh R, Cheung N, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2009;117(2):313-319.
2. Branch Vein Occlusion Study Group: Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol. 1984;98: 271-282.
3. Clarkson JG, Central Vein Occlusion Study Group: Central vein occlusion study: Photographic protocol and early natural history. Trans Am Ophthalmol Soc. 1994;92:203-215.
4. The Central Vein Occlusion Study Group: Baseline and early natural history report. Arch Ophthalmol. 1993;111:1087-1095.
5. The Central Vein Occlusion Study Group: Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The CVOS Group M Report. Ophthalmology. 1995;102:1425-1433.
6. Scott IU, Ip MS, VanVeldhuisen PC, et al; SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol. 2009;127(9):1115-1128.
7. Ip MS, Scott IU, VanVeldhuisen PC, et al; SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol. 2009;127(9):1101-1114.
8. Loewenstein A, Haller J, Bandello F, et al. 12-month evaluation of an applicator-delivered dexamethasone intravitreal implant in patients with macular edema due to branch or central retinal vein occlusion. Paper presented at: the 33rd Annual Macula Society Meeting; February 26, 2010;Tucson, AZ.
9. Campochiaro PA. Safety and efficacy of intravitreal ranibizumab (Lucentis) in patients with macular edema secondary to branch retinal vein occlusion: The BRAVO Study. Paper presented at: Retina Congress 2009; October 4, 2009; New York, NY.
10. Brown DM. Safety and efficacy of intravitreal ranibizumab (Lucentis) in patients with macular edema secondary to central retinal vein occlusion: The CRUISE Study. Paper presented at: Retina Congress 2009; October 4, 2009; New York, NY.
11. Haller JA. 6-month randomized controlled clinical trial of an intravitreal dexamethasone implant in macular edema associated with retinal vein occlusion. Paper presented at: Retina Congress 2009; October 4, 2009; New York, NY.
12. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. NEJM. 1994;331:1480-1487.
13. Pe'er J, Folberg R, Itin A, Gnessin H, Hemo I, Keshet E. Vascular endothelial growth factor upregulation in human central retinal vein occlusion. Ophthalmology. 1998;105(3):412-416.
14. Boyd SR, Zachary I, Chakravarthy U, et al. Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion. Arch Ophthalmol. 2002;120(12):1644-1650.
15. Campochiaro PA, Hafiz G, Shah SM, et al. Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. Mol Ther. 2008;16:791-799.
16. Pieramici DJ, Rabena M, Castellarin AA, et al. Ranibizumab for the treatment of macular edema associated with perfused central retinal vein occlusions. Ophthalmology. 2008;115:e47-54.
17. Spaide RF, Chang LK, Klancnik JM, et al. Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. Am J Ophthalmol. 2009;147:298-306.
18. Hayreh SS: Classification of central retinal vein occlusion. Ophthalmology. 1983;90:458-474.
19. Hayreh SS, Klugman MR, Beri M, Kimura AE, Podhajsky P. Differentiation of ischemic from non-ischemic central retinal vein occlusion during the early acute phase. Graefes Arch Clin Exp Ophthalmol. 1990;228:201-217.